Healthcare · NSE: BLUEJET
Blue Jet Healthcare
Q2 FY27 earnings and concall highlights
Q2 FY27 earnings call · Guided by management
Call held 5 Nov 2026 · Read the filing on NSEFiling
- M.Cap
- ₹9,709Cr
- P/E
- 34.0×
- 1Y return
- −10.95%
- From 52W high
- −20.8%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · standalone · ₹ Cr
| Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 376 | 165 | +127.1% | 293 | +28.2% |
| EBITDA | 119 | 55 | +116.1% | 98 | +21.1% |
| EBITDA margin | 31.6% | 33.2% | -161 bps | 33.5% | -186 bps |
| PBTProfit before tax | 137 | 69 | +99.9% | 106 | +29.7% |
| Net profit | 103 | 52 | +96.6% | 78 | +31.0% |
| EPS (₹) | 5.46 | 3.01 | +81.4% | 4.51 | +21.1% |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.
Guidance
More figures from the call
“The deployment of this would be phased over the next three years.”
In short
- 01Q2 FY27 revenue from operations was about Rs 376 crore, the highest ever, with EBITDA of about Rs 119 crore.
- 02Revenue grew 28% and EBITDA 21% over the previous quarter.
- 03Gross margin fell to 49% in Q2 as West Asia disruption raised raw material, reagent and solvent prices.
- 04Price increases with certain customers take effect from Q3; management expects a positive gross margin impact.
- 05Mahad Unit 3 KSM facility remains on track to go on stream in H2 of this year; Rs 250 crore spent so far.
- 06Vizag Phase I capex is envisaged at about Rs 1,000 crore; pre-construction under way and EC and CTE in place.
- 07QIP proceeds go to capex, working capital and general corporate purposes, deployed over three years.
- 08Management declined to give revenue guidance but cited good order visibility and a strong PI order book.
Capex
Vizag investment to be phased, with capacity tied to identified customer opportunities
Shiven Arora · Managing Director · p. 4
Vizag investment to be phased, with capacity tied to identified customer opportunities
“We are approaching this investment in a phased and disciplined manner, with capacity planning closely aligned to identified customer opportunities and the progression of our development pipeline.”
Contrast media: Mahad facility on track to go on stream in second half of this year
V.K. Singh · Chief Operating Officer · p. 5
Contrast media: Mahad facility on track to go on stream in second half of this year
“We had earlier indicated that the facility would go on stream in the second half of this year, and we remain on track to achieve that.”
Vizag Phase I to cover contrast media, intermediates, peptide fragments, sweeteners, multipurpose blocks
V.K. Singh · Chief Operating Officer · p. 5
Vizag Phase I to cover contrast media, intermediates, peptide fragments, sweeteners, multipurpose blocks
“Phase I will include significant investments in contrast media, pharmaceutical intermediates, peptide fragments, high-intensity sweeteners, and some multipurpose blocks.”
Vizag pre-construction under way; EC and Consent to Establish in place
V.K. Singh · Chief Operating Officer · p. 5
Vizag pre-construction under way; EC and Consent to Establish in place
“The pre-construction activities are underway. Statutory compliances like EC and the Consent to Establish are in place.”
Lateral entries to come from Vizag Phase I, which is some time away
V.K. Singh · Chief Operating Officer · Q&A · p. 9
Lateral entries to come from Vizag Phase I, which is some time away
“We had very clearly guided that the lateral entries will come from Vizag phase I. That is some time away.”
Capacity
Contrast media: Mahad Unit 3 builds global-scale capacity for a key contrast media KSM
V.K. Singh · Chief Operating Officer · p. 5
Contrast media: Mahad Unit 3 builds global-scale capacity for a key contrast media KSM
“Speaking specifically about manufacturing, at Mahad Unit 3, we are creating a globally scaled manufacturing capacity for a strategically critical KSM in our contrast media business.”
Current capacity may bridge lateral entries; bulk volumes when Vizag is on stream
V.K. Singh · Chief Operating Officer · Q&A · p. 9
Current capacity may bridge lateral entries; bulk volumes when Vizag is on stream
“For these lateral entries, if there are some bridging capacities that are needed, we have current capacities. We will see if we can supply from there. But the main bulk of the volumes will come when Vizag is on stream.”
High-intensity sweeteners: Vizag capacity anchored by existing clients with firm commitments
V.K. Singh · Chief Operating Officer · Q&A · p. 15
High-intensity sweeteners: Vizag capacity anchored by existing clients with firm commitments
“The Vizag capacity is being anchored by some of our existing clients from whom we have firm commitments.”
High-intensity sweeteners: Vizag sweetener capacity expected to be engaged quickly with low gestation
V.K. Singh · Chief Operating Officer · Q&A · p. 15
High-intensity sweeteners: Vizag sweetener capacity expected to be engaged quickly with low gestation
“We are very confident that the capacities that we set up will get engaged very quickly with a very low gestation.”
Order book
PI/API: PI/API has good visibility and a strong order book; Q2 not to be extrapolated
V.K. Singh · Chief Operating Officer · Q&A · p. 9
PI/API: PI/API has good visibility and a strong order book; Q2 not to be extrapolated
“Going forward, while I would not recommend that you extrapolate these Q2 numbers, all that I would say is that we have good visibility and a strong order book.”
Segments
Contrast media, PI API, artificial sweetener: Q2 sequential growth: contrast media 25%, PI API 52%, artificial sweetener down 30%
Ganesh Karuppannan · Chief Financial Officer · p. 6
Contrast media, PI API, artificial sweetener: Q2 sequential growth: contrast media 25%, PI API 52%, artificial sweetener down 30%
“This growth was driven 25% by contrast media, 52% by PI API, and a degrowth of 30% by artificial sweetener compared to previous quarter.”
Contrast media, PI API, artificial sweetener: H1 growth: contrast media 47%, PI API 19%, artificial sweetener down 2%
Ganesh Karuppannan · Chief Financial Officer · p. 7
Contrast media, PI API, artificial sweetener: H1 growth: contrast media 47%, PI API 19%, artificial sweetener down 2%
“This growth was driven 47% by contrast media, 19% by PI API, and a degrowth of 2% by artificial sweetener.”
Contrast media and PI: Some volume growth expected in contrast media, and in PI as well
Shiven Arora · Managing Director · Q&A · p. 8
Contrast media and PI: Some volume growth expected in contrast media, and in PI as well
“So, there should be some volume growth going forward. That's the similar case for the PI vertical as well.”
PI/API: PI/API has seen sequential ramp-up over the last three to four quarters
V.K. Singh · Chief Operating Officer · Q&A · p. 9
PI/API: PI/API has seen sequential ramp-up over the last three to four quarters
“I would say for the last three to four quarters, there has been sequential ramp-up.”
PI: CNS and onco products are commercial and part of the PI vertical
V.K. Singh · Chief Operating Officer · Q&A · p. 9
PI: CNS and onco products are commercial and part of the PI vertical
“I think you are mentioning about the CNS and onco opportunity. Those products are commercial and form a part of our PI vertical.”
Demand
PI and contrast media: Management cites order visibility and customer engagement in both businesses for H2 FY27
Shiven Arora · Managing Director · p. 3
PI and contrast media: Management cites order visibility and customer engagement in both businesses for H2 FY27
“As we enter the second half of FY27, we remain encouraged by the order visibility and customer engagement across both these businesses.”
Contrast media and PI: Good order visibility in contrast media and PI; management expects a good year
V.K. Singh · Chief Operating Officer · Q&A · p. 9
Contrast media and PI: Good order visibility in contrast media and PI; management expects a good year
“I won’t recommend you extrapolate but then, both cases we have good order visibility, and I think it is going to be a good year.”
Margins and costs
Q2 gross margin 49%, lower by 4% over previous quarter
Ganesh Karuppannan · Chief Financial Officer · p. 6
Q2 gross margin 49%, lower by 4% over previous quarter
“The gross margin for Q2 at 49% is lower by 4% over previous quarter.”
West Asia disruption raised prices of raw materials, reagents, solvents and catalysts
Ganesh Karuppannan · Chief Financial Officer · p. 6
West Asia disruption raised prices of raw materials, reagents, solvents and catalysts
“Following disruption of West Asia, we have seen higher prices of raw material, including reagents, solvents, and catalysts across board.”
Price increases with certain select customers take effect from Q3
Ganesh Karuppannan · Chief Financial Officer · p. 6
Price increases with certain select customers take effect from Q3
“We are reviewing the selling price increases with our customers contract by contract, and price increase with certain select customers will come into force from Q3.”
Gross margin expected to benefit from price increases in coming quarters
Ganesh Karuppannan · Chief Financial Officer · p. 7
Gross margin expected to benefit from price increases in coming quarters
“We believe with these price increase, we expect the gross margin percentage to have a positive impact in our performance in the coming quarters.”
Q2 EBITDA Rs 119 crore, 32% of operating revenue, down 1% over previous quarter
Ganesh Karuppannan · Chief Financial Officer · p. 7
Q2 EBITDA Rs 119 crore, 32% of operating revenue, down 1% over previous quarter
“EBITDA for the quarter at INR119 crores is 32% of operating revenue, a reduction of 1% over previous quarter.”
Fund raising
QIP completed; management says it strengthened the balance sheet for planned investments
Shiven Arora · Managing Director · p. 4
QIP completed; management says it strengthened the balance sheet for planned investments
“The successful completion of our qualified institutional placement has further strengthened our balance sheet and provides us with the flexibility to execute these strategic investments while maintaining a long-term perspective.”
QIP money to go to capex, part working capital and general corporate purposes
Ganesh Karuppannan · Chief Financial Officer · Q&A · p. 7
QIP money to go to capex, part working capital and general corporate purposes
“This would actually go for capital expenditure and partly for working capital and the general corporate purpose.”
Acquisitions and new business
New platforms planned: flow synthesis, peptides, GLP intermediates, biocatalysis, high-potency, solid-phase
V.K. Singh · Chief Operating Officer · p. 6
New platforms planned: flow synthesis, peptides, GLP intermediates, biocatalysis, high-potency, solid-phase
“This will also bring a high level of platform diversification, with new platforms like flow synthesis, peptides, and GLP related intermediates, biocatalysis, high-potency products, and solid-phase chemistry.”
Contrast media: New contrast media intermediate delivered and validated for an innovator in the quarter
V.K. Singh · Chief Operating Officer · p. 6
Contrast media: New contrast media intermediate delivered and validated for an innovator in the quarter
“During the quarter, we successfully delivered and validated a new contrast media intermediate for an innovator.”
Peptides: Similar progress made on a peptide fragment with an innovator
V.K. Singh · Chief Operating Officer · p. 6
Peptides: Similar progress made on a peptide fragment with an innovator
“We have also made similar progress on a peptide fragment with an innovator company.”
Contrast media: New contrast media molecule is an NCE still in clinical phase
V.K. Singh · Chief Operating Officer · Q&A · p. 7
Contrast media: New contrast media molecule is an NCE still in clinical phase
“Look, Amlan, for the contrast media, the molecule is an NCE, so it is still in clinical phase.”
PI/API: Two clinical-phase molecules will take a while to reach commercial stage
V.K. Singh · Chief Operating Officer · Q&A · p. 10
PI/API: Two clinical-phase molecules will take a while to reach commercial stage
“If you are talking of the two molecules which were in the clinical phases, they will take a while to launch, to come to commercial stage.”
Risks
Quarterly results will stay influenced by shipment schedules and product mix
Shiven Arora · Managing Director · p. 4
Quarterly results will stay influenced by shipment schedules and product mix
“Although quarterly performances will continue to be influenced by shipment schedules and product mix.”
Timing gap may pressure gross margin before revised pricing takes effect
Ganesh Karuppannan · Chief Financial Officer · p. 6
Timing gap may pressure gross margin before revised pricing takes effect
“Timing difference can put pressure on gross margin before revised pricing takes effect.”
Management cannot predict crude price, which drives many chemical and solvent costs
Ganesh Karuppannan · Chief Financial Officer · Q&A · p. 11
Management cannot predict crude price, which drives many chemical and solvent costs
“It will be too difficult for us to actually tell if the crude price has actually bottomed out or it has peaked out.”
Historical asset turns seen as too high to maintain
V.K. Singh · Chief Operating Officer · Q&A · p. 12
Historical asset turns seen as too high to maintain
“However, I would not recommend that you extrapolate them, because we believe that they are too high and we will not be able to maintain those type of asset turns.”
Net margin impact depends on input prices, product mix and timing of customer price changes
Ganesh Karuppannan · Chief Financial Officer · p. 6
Net margin impact depends on input prices, product mix and timing of customer price changes
“The net impact will depend on how input price will move in the coming quarters, the product mix, and when the customer price adjustment becomes effective.”
Other
Q2 revenue from operations about Rs 376 crore, highest ever; EBITDA about Rs 119 crore
Shiven Arora · Managing Director · p. 3
Q2 revenue from operations about Rs 376 crore, highest ever; EBITDA about Rs 119 crore
“During the quarter, we reported our highest-ever quarterly revenue from operations of approximately INR376 crores, with EBITDA of approximately INR119 crores.”
Revenue grew 28% and EBITDA 21% over the previous quarter
Shiven Arora · Managing Director · p. 3
Revenue grew 28% and EBITDA 21% over the previous quarter
“This represents sequential growth of 28% in revenue and 21% in EBITDA.”
Hyderabad R&D center is now operational with teams onboarded
Shiven Arora · Managing Director · p. 4
Hyderabad R&D center is now operational with teams onboarded
“Another important development is that our Hyderabad R&D center is now operational, with scientific teams onboarded and development activities underway.”
Fourth consecutive quarter of sequential growth
V.K. Singh · Chief Operating Officer · p. 5
Fourth consecutive quarter of sequential growth
“This has been our fourth consecutive quarter of sequential growth, and we are encouraged by the improved business performance.”
Hyderabad center operational; about 50 scientists onboarded
V.K. Singh · Chief Operating Officer · p. 5
Hyderabad center operational; about 50 scientists onboarded
“I am pleased to share that this center, that houses several synthesis labs, a world-class analytical facility, is now operational. We have onboarded approximately 50 high-performing scientists,”
Sources
- Earnings call transcript, Q2 FY27 Filed 12 Nov 2026 · 15 pages
Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

